EJHF Consensus Redefines Revascularization Role in Heart Failure With CAD

This European Journal of Heart Failure expert consensus reframes coronary revascularization as secondary to optimized guideline-directed medical therapy in heart failure with coronary artery disease, with direct implications for anticoagulant, antiplatelet, and anti-ischemic medication management.

EJHF Expert Consensus StatementEuropean Society of Cardiologyheart failurecoronary artery diseaserevascularizationantiplateletsstatinsanti-anginalsGDMT Cardiology / Anticoagulation

Background Information

Is revascularization beneficial for heart failure patients with coronary artery disease?

The role of revascularization in heart failure (HF) patients with coronary artery disease (CAD) is controversial with evolving evidence on its efficacy. Current evidence suggests revascularization may not provide significant benefit in HF with reduced ejection fraction (HFrEF) in the context of modern pharmacological treatments. Guideline-directed medical therapy (GDMT) remains crucial, and revascularization should be evaluated by a heart team considering specific patient factors such as symptoms and ischemic burden. Revascularization should be individually tailored after optimal GDMT and careful evaluation by a multidisciplinary team.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Haring B, Iaconelli A, Perera D, Velazquez EJ, Murphy GJ, Barbato E, Maron DJ, Metra M, Adamopoulos S, Petrie MC, Farmakis D, Bayes-Genis A, Böhm M

Citation: Haring B, Iaconelli A, Perera D, et al. Revascularization of coronary artery disease in heart failure. A European Journal of Heart Failure Expert Consensus Statement. European journal of heart failure. 2026. doi:10.1093/ejhf/xuag230

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Thanks for the feedback!

🔒

Deep Analysis: Subscribers Only

Subscribers receive access to a complete clinical analysis, available online and as a downloadable PDF.

Executive Summary

Study Design

Patient Population

Primary Outcomes

Secondary Outcomes & Safety Profile

Pharmacist Implications

Clinical Pearls

Limitations

Controversies & Evidence Gaps

Cost & Logistics

Want the full analysis?

Subscribe to PharmD Signal for unrestricted access to every deep analysis, plus PDF reports, GRADE evidence grades, and pharmacist implications for every article we publish.

Become a Subscriber →